What changed from existing technology?
This study looks at how different ways of taking blood-thinning medicines for heart rhythm problems affect healthcare costs, especially for people with lower income.
This study is the first to use a two-part model to estimate healthcare costs related to atrial fibrillation treatment patterns, considering socioeconomic factors.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 3
lowed for five years, with Scottish data linked from inpatient, outpatient, prescribing, and care-home records. Four groups
Abstract ↗o initiate treatment and discontinuation or cessation remain a significant issue, especially among socioeconomically disadvantaged populations. The aim o
Abstract ↗OpenAlex author affiliations: Bristol-Myers Squibb (United Kingdom)
Abstract ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
This model could help healthcare providers understand how different treatment approaches affect costs and identify areas where socioeconomic factors may influence treatment outcomes.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.
Evidence and sources
View paper and author affiliations
Open original researchInequalities in oral anticoagulant treatment patterns: a two-part model to estimate healthcare costs associated with atrial fibrillationThe European Journal of Health Economics · Published 2026-09-30 ↗Author institutions and listed legal entities are separated; only verified exchange and ticker data is linked.